HK1127295A1 - Antiviral phosphinate compounds - Google Patents

Antiviral phosphinate compounds

Info

Publication number
HK1127295A1
HK1127295A1 HK09106472.5A HK09106472A HK1127295A1 HK 1127295 A1 HK1127295 A1 HK 1127295A1 HK 09106472 A HK09106472 A HK 09106472A HK 1127295 A1 HK1127295 A1 HK 1127295A1
Authority
HK
Hong Kong
Prior art keywords
phosphinate compounds
antiviral
antiviral phosphinate
compounds
phosphinate
Prior art date
Application number
HK09106472.5A
Other languages
English (en)
Inventor
Anthony Casarez
Kleem Chaudhary
Aesop Cho
Michael Clarke
Edward Doerffler
Maria Fardis
Choung U Kim
Hyungjung Pyun
Xiaoning C Sheng
Jianying Wang
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of HK1127295A1 publication Critical patent/HK1127295A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK09106472.5A 2006-07-07 2009-07-16 Antiviral phosphinate compounds HK1127295A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81948806P 2006-07-07 2006-07-07
US83290806P 2006-07-24 2006-07-24
PCT/US2007/015664 WO2008005565A2 (en) 2006-07-07 2007-07-06 Antiviral phosphinate compounds

Publications (1)

Publication Number Publication Date
HK1127295A1 true HK1127295A1 (en) 2009-09-25

Family

ID=38626760

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09106472.5A HK1127295A1 (en) 2006-07-07 2009-07-16 Antiviral phosphinate compounds

Country Status (20)

Country Link
US (4) US20090227491A1 (xx)
EP (2) EP2043658B1 (xx)
JP (3) JP2009542698A (xx)
KR (1) KR20090026216A (xx)
CN (1) CN102532198A (xx)
AR (1) AR061840A1 (xx)
AT (1) ATE554776T1 (xx)
AU (1) AU2007269567B2 (xx)
BR (1) BRPI0713961A2 (xx)
CA (1) CA2656356C (xx)
EA (1) EA018098B1 (xx)
ES (2) ES2388969T3 (xx)
HK (1) HK1127295A1 (xx)
HR (1) HRP20090076A2 (xx)
IL (1) IL195489A0 (xx)
MX (1) MX2009000236A (xx)
NO (1) NO20090596L (xx)
TW (1) TW200819460A (xx)
WO (1) WO2008005565A2 (xx)
ZA (1) ZA200810400B (xx)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
EP2043658B1 (en) * 2006-07-07 2012-04-25 Gilead Sciences, Inc. Antiviral phosphinate compounds
JP2011519364A (ja) * 2008-04-15 2011-07-07 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規大環状阻害剤
JP5690286B2 (ja) * 2009-03-04 2015-03-25 イデニク プハルマセウティカルス，インコーポレイテッド ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
WO2010151472A1 (en) * 2009-06-23 2010-12-29 Gilead Sciences, Inc. Combination of a ns5b polymerase inhibitor and a hcv ns3 protease inhibitor for the treatment of hcv
US8476225B2 (en) 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds
WO2011156757A1 (en) * 2010-06-10 2011-12-15 Gilead Sciences, Inc. Combination of anti-hcv compounds with ribavirin for the treatment of hcv
WO2012087596A1 (en) 2010-12-20 2012-06-28 Gilead Sciences, Inc. Combinations for treating hcv
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6073897B2 (ja) 2011-09-16 2017-02-01 ギリアド ファーマセット エルエルシー Ｈｃｖを処置するための方法
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CN103826627B (zh) 2011-10-21 2016-02-24 艾伯维公司 包含至少两种直接抗病毒剂和利巴韦林的组合物在制备治疗hcv的药物中的用途
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
WO2013059638A1 (en) 2011-10-21 2013-04-25 Abbvie Inc. Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
AU2012392557B2 (en) 2012-10-19 2017-06-01 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014070974A1 (en) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
ES2771458T3 (es) 2013-01-31 2020-07-06 Gilead Pharmasset Llc Formulación de combinación de dos compuestos antivirales
CN105164148A (zh) 2013-03-07 2015-12-16 百时美施贵宝公司 丙型肝炎病毒抑制剂
CN103539831B (zh) * 2013-09-29 2016-02-03 北京林业大学 山杏α-葡萄糖苷酶抑制肽及其制备方法和用途
CN103539833B (zh) * 2013-09-29 2016-02-03 北京林业大学 高活性α-葡萄糖苷酶抑制肽及其制备方法和用途
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
US11738013B2 (en) 2016-05-27 2023-08-29 Gilead Sciences, Inc. Methods for treating hepatitis B virus infections using NS5A, NS5B or NS3 inhibitors

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
ES2083580T3 (es) 1990-06-13 1996-04-16 Arnold Glazier Profarmacos de fosforo.
ES2118069T3 (es) 1990-09-14 1998-09-16 Acad Of Science Czech Republic Profarmacos de fosfonatos.
DE4308096A1 (de) 1993-03-13 1994-09-15 Hoechst Ag Prodrug-Derivate von Enzyminhibitoren mit Hydroxylgruppen, Verfahren zu deren Herstellung und ihre Verwendung
ATE199906T1 (de) 1993-06-29 2001-04-15 Mitsubishi Chem Corp Phosphonat-nukleotid ester-derivate
JP4086314B2 (ja) 1993-09-17 2008-05-14 ギリアード サイエンシーズ， インコーポレイテッド ヌクレオチドアナログ
JPH07183249A (ja) 1993-12-22 1995-07-21 Nec Yamagata Ltd イオン注入工程管理方法
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US5968788A (en) * 1995-08-28 1999-10-19 Toray Industries, Inc. Method for producing folic acid
US6004977A (en) * 1996-12-27 1999-12-21 Hoechst Marion Roussel, Inc. N-(pyridinylamino) isoindolines and related compounds
DE19843360A1 (de) * 1998-09-22 2000-03-30 Hassan Jomaa Phosphororganische Verbindungen und ihre Verwendung
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
US7173004B2 (en) * 2003-04-16 2007-02-06 Bristol-Myers Squibb Company Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus
PL1778702T3 (pl) 2004-07-16 2011-12-30 Gilead Sciences Inc Związki przeciwwirusowe
WO2007001406A2 (en) 2004-10-05 2007-01-04 Chiron Corporation Aryl-containing macrocyclic compounds
JP2008538750A (ja) * 2005-04-13 2008-11-06 アステックス、セラピューティックス、リミテッド 医薬化合物
EP2305697A3 (en) * 2005-07-25 2011-07-27 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
EP1919898B1 (en) 2005-07-29 2011-01-26 Tibotec Pharmaceuticals Macrocyclic inhibitors of hepatitis c virus
PE20070211A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
US7772183B2 (en) * 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2043658B1 (en) * 2006-07-07 2012-04-25 Gilead Sciences, Inc. Antiviral phosphinate compounds
US8293705B2 (en) * 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
WO2010151472A1 (en) 2009-06-23 2010-12-29 Gilead Sciences, Inc. Combination of a ns5b polymerase inhibitor and a hcv ns3 protease inhibitor for the treatment of hcv
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Also Published As

Publication number Publication date
NO20090596L (no) 2009-04-01
EP2043658A2 (en) 2009-04-08
KR20090026216A (ko) 2009-03-11
US20090227491A1 (en) 2009-09-10
WO2008005565A9 (en) 2009-01-29
TW200819460A (en) 2008-05-01
US8674088B2 (en) 2014-03-18
BRPI0713961A2 (pt) 2012-11-27
EP2043658B1 (en) 2012-04-25
JP2012107061A (ja) 2012-06-07
US8586744B2 (en) 2013-11-19
EP2422791A1 (en) 2012-02-29
AR061840A1 (es) 2008-09-24
EA200900154A1 (ru) 2009-06-30
EA018098B1 (ru) 2013-05-30
ZA200810400B (en) 2011-12-28
AU2007269567B2 (en) 2012-11-08
HRP20090076A2 (en) 2009-05-31
JP6010640B2 (ja) 2016-10-19
US7893264B2 (en) 2011-02-22
WO2008005565A2 (en) 2008-01-10
ES2531315T3 (es) 2015-03-12
ES2388969T3 (es) 2012-10-22
CA2656356C (en) 2013-04-09
US20110082112A1 (en) 2011-04-07
CN102532198A (zh) 2012-07-04
US20110081314A1 (en) 2011-04-07
JP2015083605A (ja) 2015-04-30
ATE554776T1 (de) 2012-05-15
WO2008005565A3 (en) 2008-05-02
US20080057031A1 (en) 2008-03-06
CA2656356A1 (en) 2008-01-10
JP2009542698A (ja) 2009-12-03
AU2007269567A1 (en) 2008-01-10
IL195489A0 (en) 2009-09-01
MX2009000236A (es) 2009-01-23
EP2422791B1 (en) 2014-12-17

Similar Documents

Publication Publication Date Title
ZA200810400B (en) Antiviral phosphinate compounds
IL246547A0 (en) Antiviral compounds
IL193107A0 (en) Hetero-bycyclic antiviral compounds
ZA201000614B (en) Antiviral compounds
GB0602424D0 (en) Compounds
EP2234623A4 (en) ANTIVIRAL CONNECTIONS
GB0602046D0 (en) Compounds
HK1135989A1 (en) Polyfluoroether-based phosphates
ZA200904053B (en) Phosphonate compounds
EP1984379A4 (en) ANTI-ARENAVIRAL COMPOUNDS
GB0614034D0 (en) Antiviral compounds
EP2082022A4 (en) COMPOUNDS
EP2004174A4 (en) NAPHTHALENEDIONED COMPOUNDS
GB0602042D0 (en) Compounds
EP1973905A4 (en) COMPOUNDS
AP2009004767A0 (en) Cubstituted azolin-2-yl-amino compounds
EP2016069A4 (en) BISPYRIDINIUMVERBINDUNGEN
GB0602560D0 (en) Compounds
GB0602412D0 (en) Compounds
GB0600427D0 (en) Compounds
ZA201107393B (en) Antiviral phosphinate compounds
AP2008004721A0 (en) Antiviral phosphinate compounds
GB0622798D0 (en) Phosphorus compounds
ZA201000662B (en) Antiviral compounds
GB0602454D0 (en) Compounds

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160706